A ix-month randomized clinical trial comparing the intraocular preure-lowering efficacy of bimatoprot and latanoprot in patient with ocular hypertenion or glaucoma

Purpoe To compare the intraocular preure (IOP)-lowering efficacy and afety of topical bimatoprot 0.03% with latanoprot 0.005%. Deign Multicenter, randomized, invetigator-maked clinical trial. Method After wahout of glaucoma medication, ocular hypertenion or glaucoma patient were randomly aigned to once-daily bimatoprot 0.03% (n = 133) or latanoprot 0.005% (n = 136) for 6 month. The primary outcome meaure wa mean change from baeline IOP (8 am, 12 pm, 4 pm). econdary meaure included mean IOP, ophthalmologic examination, advere event, and the percentage of patient reaching pecific target IOP. Reult Mean change from baeline IOP wa ignificantly greater for bimatoprot patient than for latanoprot patient at all meaurement on each tudy viit; 1.5 mm Hg greater at 8 am (P < .001), 2.2 mm Hg greater at 12 pm (P < .001), and 1.2 mm Hg greater at 4 pm (P = .004) at month 6. At the end of the tudy, the percentage of patient achieving a ≥20% IOP decreae wa 69% to 82% with bimatoprot and 50% to 62% with latanoprot (P ≤ .003). In addition, the ditribution of patient achieving target preure in each range (≤13 to ≤ 15 mm Hg, >15 to ≤ 18 mm Hg, and > 18 mm Hg) howed that bimatoprot produced lower target preure compared with latanoprot at all time meaured (P ≤ .026). Few patient were dicontinued for advere event (6 on bimatoprot; 5 on latanoprot). On ophthalmologic examination, conjunctival hyperemia (P < .001) and eyelah growth (P = .064) were more common in bimatoprot patient. Concluion Bimatoprot i more effective than latanoprot in lowering IOP. Both drug were well tolerated, with few dicontinuation for advere event.